Addex Therapeutics Management
Management criteria checks 2/4
Addex Therapeutics' CEO is Tim Dyer, appointed in Jan 2002, has a tenure of 22.33 years. directly owns 13.14% of the company’s shares, worth CHF1.03M. The average tenure of the management team and the board of directors is 7.2 years and 8.9 years respectively.
Key information
Tim Dyer
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 22.3yrs |
| CEO ownership | 13.1% |
| Management average tenure | 7.2yrs |
| Board average tenure | 8.9yrs |
Recent management updates
Recent updates
Here's Why Addex Therapeutics (VTX:ADXN) Must Use Its Cash Wisely
Mar 03
Here's Why Addex Therapeutics (VTX:ADXN) Must Use Its Cash Wisely
May 11Is Addex Therapeutics (VTX:ADXN) In A Good Position To Invest In Growth?
Nov 23Increases to CEO Compensation Might Be Put On Hold For Now at Addex Therapeutics Ltd (VTX:ADXN)
Jun 10Is Addex Therapeutics (VTX:ADXN) In A Good Position To Invest In Growth?
Mar 07What Type Of Returns Would Addex Therapeutics'(VTX:ADXN) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?
Jan 12CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -CHF11m |
| Sep 30 2023 | n/a | n/a | -CHF11m |
| Jun 30 2023 | n/a | n/a | -CHF13m |
| Mar 31 2023 | n/a | n/a | -CHF17m |
| Dec 31 2022 | n/a | n/a | -CHF21m |
| Sep 30 2022 | n/a | n/a | -CHF22m |
| Jun 30 2022 | n/a | n/a | -CHF21m |
| Mar 31 2022 | n/a | n/a | -CHF19m |
| Dec 31 2021 | n/a | n/a | -CHF15m |
| Sep 30 2021 | n/a | n/a | -CHF13m |
| Jun 30 2021 | n/a | n/a | -CHF13m |
| Mar 31 2021 | n/a | n/a | -CHF11m |
| Dec 31 2020 | CHF917k | CHF454k | -CHF13m |
| Sep 30 2020 | n/a | n/a | -CHF14m |
| Jun 30 2020 | n/a | n/a | -CHF15m |
| Mar 31 2020 | n/a | n/a | -CHF16m |
| Dec 31 2019 | CHF709k | CHF429k | -CHF15m |
| Sep 30 2019 | n/a | n/a | -CHF13m |
| Jun 30 2019 | n/a | n/a | -CHF12m |
| Mar 31 2019 | n/a | n/a | -CHF6m |
| Dec 31 2018 | CHF2m | n/a | -CHF2m |
Compensation vs Market: Insufficient data to establish whether Tim's total compensation is reasonable compared to companies of similar size in the Swiss market.
Compensation vs Earnings: Tim's compensation has increased whilst the company is unprofitable.
CEO
Tim Dyer (55 yo)
22.3yrs
Tenure
Mr. Timothy Mark Dyer, also known as Tim, has been Chief Executive Officer at Addex Therapeutics Ltd. since June 1, 2013. Mr. Dyer co-founded Addex Therapeutics Ltd.(also known as Addex Pharmaceuticals Lt...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 22.3yrs | no data | 13.14% CHF 1.0m | |
| Chief Medical Officer & Director | 7.5yrs | no data | no data | |
| Head of Finance | 6.9yrs | no data | no data | |
| Head of Translational Science | 2.8yrs | no data | no data |
7.2yrs
Average Tenure
55.5yo
Average Age
Experienced Management: ADXN's management team is seasoned and experienced (7.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 9.3yrs | no data | 13.14% CHF 1.0m | |
| Chief Medical Officer & Director | 7.3yrs | no data | no data | |
| Independent Director | 5.9yrs | CHF41.29k | no data | |
| Non-Executive Director | 8.9yrs | CHF89.65k | 1.06% CHF 83.3k | |
| Independent Chairman of the Board | 15.1yrs | CHF155.75k | 1.96% CHF 153.0k |
8.9yrs
Average Tenure
66yo
Average Age
Experienced Board: ADXN's board of directors are considered experienced (8.9 years average tenure).